pharm14520240209161306384EMO_en_20240209161306506.png

過去のプログラムはこちら

罫線.png

罫線1

創薬サイエンス_バナーRGB_w250px.gif

創薬サイエンス

7_10051-2：東京大学.jpg

創薬等先端技術支援基盤プラットフォーム

罫線2

第9回精神薬学会バナー500×200.jpg

第9回日本精神薬学会総会・学術集会

第35回日本医療薬学会年会バナー.jpg

第35回日本医療薬学会年会

罫線3

General information

Overview

Announcements(26)

Timetable

Thu. Mar 27, 2025

Fri. Mar 28, 2025

Sat. Mar 29, 2025

Program & Abstract

Sessions

Search presentations

Selected programs of presentations in English

Download Abstracts PDF

Registration

Registration (Non-presenters under 4th year underg

For Participants and Presenters

Participation Certificate PDF

For Participants

For Presenters

How to use "Confit mobile meeting app"

Exhibition

Companies（Equipment exhibits）

Companies（Medical supplies）

Bibliographic information retrieval system

Companies（Books）

Abstract Submission (Oral/Poster Presentation)

Abstract Submission

header_en_20240313161625152.png

app_icon.png

Profile management

Bookmark

Announcements

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts.<br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Aiming for zero cervical cancer - message from a bereaved pharmacist -

ASTEM's purpose is to "in providing relief from the anxiety of people's health-related problems", acts as a bridge between medical professionals, pharmaceutical companies, local governments, and insurers, and are developing active open innovation with different industries and academia. The theme of this session is cervical cancer prevention and awareness. Cervical cancer is often caused by people in their 30s and 40s, and there is a risk of loss of fertility and long-term sequelae. Therefore, there is suffering for patients and their families that cannot be expressed simply by incidence and mortality rates. As a preventive method for cervical cancer, regular vaccination with the human papillomavirus (HPV) vaccine, which is the primary prevention method, was implemented in April 2013. However, in June of the same year, following reports of various symptoms after vaccination, measures were taken to suspend active vaccination. As a result, the vaccination rate fell to less than 1%. After that, active recommendations were resumed in April 2022 because there was no evidence of various symptoms and the association with the HPV vaccine, but the vaccination rate was not far from the 70% before the withholding. In this session, speakers from various positions will introduce activities to promote the HPV vaccine and consider what we can do to eliminate cervical cancer.

As an efforts to "in providing relief from the anxiety of people's health-related issues" —Promoting HPV vaccination—

The 145th Annual Meeting of the Pharmaceutical Society of Japan (Fukuoka)

Presentation Information

[SS12-2]Aiming for zero cervical cancer - message from a bereaved pharmacist -

Password required to view